HOOK insider filings
HOOKIPA Pharma Inc. — 35 most recent insider filings (SEC Forms 3/4/5) from EDGAR, normalized by FilingPulse. Latest filing: 2025-10-09. Screen HOOK transaction legs live →
Insider transaction summary — last 90 days
No insider filings (Forms 3/4/5) for HOOK between 2026-07-10 and 2026-10-08. The table below lists the most recent filings on record.
Recent insider filings — HOOKIPA Pharma Inc.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-10-09 | 4 | Peters Malte — Chief Executive Officer, Director | Sale (S): 25,172 @ $0.82 | EDGAR |
| 2025-07-23 | 4 | Peters Malte — Chief Executive Officer, Director | Sale (S): 29,176 @ $0.92 | EDGAR |
| 2025-07-23 | 4 | Coelho Mary Theresa — EVP and CFO, Director | Sale (S): 13,609 @ $0.92 | EDGAR |
| 2024-07-24 | 4 | Peters Malte — Chief Executive Officer, Director | Grant/award (A): 108,695 @ $0 | EDGAR |
| 2024-07-24 | 4 | Coelho Mary Theresa — EVP and CFO, Director | Grant/award (A): 69,875 @ $0 | EDGAR |
| 2024-07-24 | 4 | Cassidy Sean A — Director | Grant/award (A): 9,800 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | van de Winkel Jan — Director | Grant/award (A): 98,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Peters Malte — Director | Grant/award (A): 49,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Kaufman David Ross — Director | Grant/award (A): 49,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Reilly Timothy P. — Director | Grant/award (A): 49,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Coelho Mary Theresa — Director | Grant/award (A): 49,000 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | O'Neill Julie — Director | Grant/award (A): 49,000 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Winderlich Mark — Chief Development Officer | Grant/award (A): 250,000 (derivative) @ $0 · Grant/award (A): 50,000 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Kandera Reinhard — Chief Financial Officer, Director | Grant/award (A): 406,200 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Orlinger Klaus — Chief Scientific Officer | Grant/award (A): 367,300 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Necina Roman — Chief Operations Officer | Grant/award (A): 367,300 (derivative) @ $0 | EDGAR |
| 2024-04-17 | 4 | Aldag Jorn — Chief Executive Officer, Director | Grant/award (A): 971,400 (derivative) @ $0 | EDGAR |
| 2023-08-22 | 4 | Kandera Reinhard — Chief Financial Officer, Director | Purchase (P): 7,000 @ $0.72 | EDGAR |
| 2023-08-17 | 4 | Kandera Reinhard — Chief Financial Officer, Director | Purchase (P): 8,000 @ $0.71 | EDGAR |
| 2023-07-11 | 4 | Aldag Jorn — Chief Executive Officer, Director | Purchase (P): 5,000 @ $0.81 · Purchase (P): 5,000 @ $0.83 | EDGAR |
| 2023-07-07 | 4 | Aldag Jorn — Chief Executive Officer, Director | Purchase (P): 5,000 @ $0.89 | EDGAR |
| 2023-07-05 | 4 | Aldag Jorn — Chief Executive Officer, Director | Purchase (P): 5,000 @ $0.89 | EDGAR |
| 2023-07-03 | 4 | Kandera Reinhard — Chief Financial Officer, Director | Purchase (P): 12,000 @ $0.88 | EDGAR |
| 2023-06-09 | 4 | Peters Malte — Director | Grant/award (A): 52,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Reilly Timothy P. — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | van de Winkel Jan — Director | Grant/award (A): 52,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Kaufman David Ross — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | Coelho Mary Theresa — Director | Grant/award (A): 52,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | O'Neill Julie — Director | Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Orlinger Klaus — Chief Scientific Officer | Grant/award (A): 194,200 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Necina Roman — Chief Development Officer | Grant/award (A): 112,100 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Schlienger Katia — Chief Medical Officer | Grant/award (A): 184,000 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Baker Christine D. — Chief Operating Officer | Grant/award (A): 275,800 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Kandera Reinhard — Chief Financial Officer, Director | Grant/award (A): 214,800 (derivative) @ $0 | EDGAR |
| 2023-04-18 | 4 | Aldag Jorn — Chief Executive Officer, Director | Grant/award (A): 513,600 (derivative) @ $0 | EDGAR |
Recent 8-K events — HOOKIPA Pharma Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2025-07-29 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-07-18 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-05-22 | 8-K | 1.01 — Entry into a Material Definitive Agreement 1.02 — Termination of a Material Definitive Agreement 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-20 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-29 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-10 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-07 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-01-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2024-11-20 | 8-K | 8.01 — Other Events | EDGAR |
| 2024-11-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=HOOK returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →